Stammdaten
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Unternehmen & Branche
| Name | CITIUS ONCOLOGY, INC. |
|---|---|
| Ticker | CTOR |
| CIK | 0001851484 |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - General |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 74,0 Mio. USD |
| Beta | 3,43 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 3,944,111 | -5,534,069 | -0.06 | 109,973,406 | 58,413,701 |
| 2025-09-30 | 10-K | -24,761,369 | -0.34 | 100,942,881 | 44,866,231 | |
| 2025-06-30 | 10-Q | -5,369,956 | -0.08 | 91,709,079 | 32,397,913 | |
| 2025-03-31 | 10-Q | -7,735,552 | -0.11 | 91,439,365 | 35,642,632 | |
| 2024-12-31 | 10-Q | -6,659,205 | -0.09 | 90,481,481 | 41,289,612 | |
| 2024-09-30 | 10-K | -21,148,747 | -0.31 | 84,368,878 | 46,140,339 | |
| 2024-06-30 | 10-Q | -4,772,850 | -0.07 | 49,193,627 | 17,030,861 | |
| 2024-03-31 | 10-Q | -4,835,546 | -0.07 | 48,679,257 | 19,846,711 | |
| 2023-12-31 | 10-K | 2,419,304 | 0.27 | 72,623,594 | -1,987,562 | |
| 2023-12-31 | 10-Q | -4,727,403 | -0.07 | 72,623,594 | 22,725,257 | |
| 2023-09-30 | 10-Q | 157,943 | 0.02 | 70,713,071 | 25,535,660 | |
| 2023-09-30 | 10-K | -12,697,241 | -0.19 | 47,734,895 | 25,535,660 | |
| 2023-06-30 | 10-Q | 616,296 | 0.07 | 69,850,424 | -1,968 | |
| 2023-03-31 | 10-Q | 611,725 | 0.07 | 68,818,033 | 197,586 | |
| 2022-12-31 | 10-K | 380,811 | 0.12 | 68,190,364 | 345,508 | |
| 2021-12-31 | 10-K | -10,113 | 126,422 | -10,113 | ||
| 2021-09-30 | 10-Q | -10,113 | -10,113 | |||
| 2021-06-30 | 10-Q | -724 | -10,113 | |||
| 2021-03-31 | 10-Q | -9,389 | -9,389 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.